Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial-Reference-Cited by-同舟云学术

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

Published:2008-06 Issue:6 Volume:9 Page:533-542
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Park Byeong-Ho,Hwang Taeho,Liu Ta-Chiang,Sze Daniel Y,Kim Jae-Seok,Kwon Hyuk-Chan,Oh Sung Yong,Han Sang-Young,Yoon Jin-Han,Hong Sook-Hee,Moon Anne,Speth Kelly,Park Chohee,Ahn Young-Joo,Daneshmand Manijeh,Rhee Byung Geon,Pinedo Herbert M,Bell John C,Kirn David H

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Replication-selective virotherapy for cancer: biological principles, risk management and future directions;Kirn;Nat Med,2001

2. Recent progress in the battle between oncolytic viruses and tumours;Parato;Nat Rev Cancer,2005

3. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress;Liu;Nat Clin Pract Oncol,2007

4. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma;Mastrangelo;Cancer Gene Ther,1999

5. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction;Yang;J Clin Invest,2005

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials;Vaccines;2024-09-03

2. oHSV2-mGM repolarizes TAMs and cooperates with αPD1 to reprogram the immune microenvironment of residual cancer after radiofrequency ablation;Biomedicine & Pharmacotherapy;2024-09

3. An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer;Vaccines;2024-08-23

4. Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice;Biomedicines;2024-08-12

5. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside;Experimental Hematology & Oncology;2024-08-01